
Novartis Reports Results of Canakinumab in P-III CANOPY-1 Study for the Treatment of Lung Cancer
Shots: The P-III CANOPY-1 trial evaluates canakinumab (ACZ885) + pembrolizumab + platinum-based doublet CT vs PBO + pembrolizumab + CT in patients with LA or […]